Important Notice for Regeneron Pharmaceuticals, Inc. Shareholders
The Gross Law Firm announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of shareholders of Regeneron Pharmaceuticals, Inc. (REGN) who purchased shares during the period from January 1, 2023, to November 1, 2024. The lawsuit alleges that Regeneron Pharmaceuticals, Inc. and certain of its top executives violated the Securities Exchange Act of 1934.
Class Period and Eligibility
The class period for this lawsuit is from January 1, 2023, to November 1, 2024. If you purchased shares of Regeneron Pharmaceuticals, Inc. (REGN) during this period, you may be a member of the class and eligible to receive compensation.
Allegations against Regeneron Pharmaceuticals, Inc.
The complaint alleges that Regeneron Pharmaceuticals, Inc. and certain top executives made false and misleading statements regarding the company’s financial condition and business prospects. Specifically, the complaint alleges that Regeneron Pharmaceuticals, Inc. failed to disclose material information about the potential safety risks and efficacy of its Eylea product, which is used to treat various eye conditions. The complaint also alleges that the company failed to disclose that its sales growth was due in part to illegal, off-label marketing of Eylea.
Lead Plaintiff Appointment and Next Steps
The Gross Law Firm is seeking to be appointed as lead plaintiff in this case. If you purchased shares of Regeneron Pharmaceuticals, Inc. (REGN) during the class period and wish to serve as lead plaintiff, you must move the Court no later than March 26, 2025. If you wish to join the case as a class member, you need take no action at this time.
Potential Impact on Individual Shareholders
If the allegations in the class action lawsuit are proven, shareholders may be entitled to compensation for their losses. The exact amount of damages will depend on the outcome of the case and the size of their investment in Regeneron Pharmaceuticals, Inc. (REGN).
Potential Impact on the World
The class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN) is significant because it raises important issues about corporate governance and transparency in the pharmaceutical industry. If the allegations are proven, it could lead to increased scrutiny of other pharmaceutical companies and their marketing practices. It could also lead to increased regulation of the pharmaceutical industry and greater transparency around clinical trials and drug safety.
Conclusion
If you purchased shares of Regeneron Pharmaceuticals, Inc. (REGN) during the class period listed in the lawsuit, you may be eligible to receive compensation. The Gross Law Firm is seeking to be appointed as lead plaintiff in this case and encourages shareholders to contact them to discuss their options. The outcome of this case could have significant implications for the pharmaceutical industry and investor trust.
- Class action lawsuit filed against Regeneron Pharmaceuticals, Inc. (REGN)
- Allegations of false and misleading statements regarding financial condition and business prospects
- Potential impact on individual shareholders: compensation for losses
- Potential impact on the world: increased scrutiny of pharmaceutical industry, regulation, transparency
